uploads/2019/01/Graph-4-13-1.png

What Analysts Project for JNJ’s Margins and Interest Expenses

By

Updated

Margin projections

In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) projected its adjusted pre-tax operating margin in fiscal 2019 to be slightly higher on a YoY basis. Wall Street analysts expect Johnson & Johnson to report operating margin of 30.88% in fiscal 2019.

According to Johnson & Johnson’s fourth-quarter earnings conference call, the company is focused on investing in its high margin businesses such as the Pharmaceutical segment and the Medical Device segment to return to above-market growth by 2020. According to the company’s fourth-quarter earnings conference call, Johnson & Johnson’s Pharmaceutical business has the best-in-class margins, while its Medical Device business has higher margins as compared to its peers. Johnson & Johnson expects the biggest opportunity for margin expansion to arise from its Consumer business, which currently has lower margins as compared to peers.

Article continues below advertisement

Wall Street analysts expect Johnson & Johnson to report a gross margin of 72.36% in fiscal 2019, a YoY drop of three basis points. The company is expected to report a gross margin of 72.61% in fiscal 2020, a YoY rise of 25 basis points. Johnson & Johnson is also expected to report a gross margin of 72.72% in fiscal 2021, a YoY rise of 11 basis points.

Interest projections

Wall Street analysts expect Johnson & Johnson to report net interest expenses of $371.22 million in fiscal 2019, a YoY drop of 5.78%. The company is expected to report a net interest expense of $360.33 million in fiscal 2020, a YoY drop of 2.93%. Johnson & Johnson is also expected to report a net interest expense of $375.67 million in fiscal 2021, a YoY rise of 4.26%.

The company expects to report net interest expense in the range of $100 million to $200 million in fiscal 2019. The company expects to benefit from lower debt levels and higher interest income in fiscal 2019.

In the next article, we will discuss Johnson & Johnson’s SG&A and R&D expenses for fiscal 2019 in greater detail.

Advertisement

More From Market Realist